Biology Reference
In-Depth Information
Verghese MW, McConnell RT, Lenhard JM, Hamacher L, Jin SL (1995) Regulation of distinct
cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human mono-
cytic cells. Mol Pharmacol 47:1164-1171
Waki Y, Horita T, Miyamoto K-i, Ohya K, Kasugai S (1999) Effects of XT-44, a phosphodiester-
ase 4 Inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects.
Jpn J Pharmacol 79:477-483
Wani MR, Fuller K, Kim NS, Choi Y, Chambers T (1999) Prostaglandin E2 cooperates with
TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of
differentiation, cell spreading, and fusion. Endocrinology 140:1927-1935
Wilson NJ, Cross M, Nguyen T, Hamilton JA (2005) cAMP inhibits CSF-1-stimulated tyrosine
phosphorylation but augments CSF-1R-mediated macrophage differentiation and ERK activa-
tion. FEBS J 272:4141-4152
Wilson JM, Ross WG, Agbai ON, Frazier R, Figler RA, Rieger J, Linden J, Ernst PB (2009)
The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells.
J Immunol 182:4616-4623
Xaus J, Valledor AF, Cardo M, Marques L, Beleta J, Palacios JM, Celada A (1999) Adenosine
inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages
through the induction of p27kip-1 expression. J Immunol 163:4140-4149
Yamagami H, Nishioka T, Ochiai E, Fukushima K, Nomura M, Kasugai S, Moritani S,
Yokogawa K, Miyamoto K-i (2003) Inhibition of osteoclastogenesis by a phosphodiesterase
4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2. Biochem
Pharmacol 66:801-807
Zhu N, Cui J, Qiao C, Li Y, Ma Y, Zhang J, Shen B (2008) cAMP modulates macrophage
development by suppressing M-CSF-induced MAPKs activation. Cell Mol
Immunol
5:153-157
Zuloff-Shani A, Kachel E, Frenkel O, Orenstein A, Shinar E, Danon D (2004) Macrophage
suspensions prepared from a blood unit for treatment of refractory human ulcers. Transfus
Apher Sci 30:163-167
